| Registro completo |
| Provedor de dados: |
BJID
|
| País: |
Brazil
|
| Título: |
Weight-based combination therapy with peginterferon alpha-2b and ribavirin for Naïve, relapser and non-responder patients with chronic hepatitis C
|
| Autores: |
Gonçales Jr.,Fernando Lopes
Vigani,Aline
Gonçales,Neiva
Barone,Antonio Alci
Araújo,Evaldo
Focaccia,Roberto
Oliveira,Umbeliana
Coelho,Henrique Sérgio Morais
Paixao,Jacqueline
Perez,Renata
Lobato,Cirley
Weirich,Judith
Rosa,Heitor
Borges,Andrelina
Vila,Ricardo
Corrêa-Giannella,Maria Lúcia
Ferraz,Maria Lúcia Gomes
|
| Data: |
2006-10-01
|
| Ano: |
2006
|
| Palavras-chave: |
Hepatitis C
Interferon alpha-2b
Therapy
|
| Resumo: |
Combination therapy with pegylated interferon and ribavirin is considered the new standard therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment with weight-based peginterferon alpha-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48 weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin) patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was 54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was significantly higher in patients with the non-1 genotype (67%) compared to those with genotype 1 (45%). In relapsers and non-responders, SVR was, respectively, 69% and 24% in patients with genotype 1 and 43% and 73% in those with genotype non-1. There were no significant differences in SVR rates among the three body weight ranges (< 65 kg, 65-85 kg and > 85 kg) in any of the subgroups. Early virological response (EVR) was reached by 78%, 81% and 58% of naïve, relapser and non-responder patients, respectively, and among those with EVR, 63%, 67% and 61%, respectively, subsequently achieved SVR. All of the non-responder patients who did not have EVR reached SVR. Treatment was discontinued in 13% of the patients, due to loss to follow-up, hematological abnormalities or depression.
|
| Tipo: |
Info:eu-repo/semantics/article
|
| Idioma: |
Inglês
|
| Identificador: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000500002
|
| Editor: |
Brazilian Society of Infectious Diseases
|
| Relação: |
10.1590/S1413-86702006000500002
|
| Formato: |
text/html
|
| Fonte: |
Brazilian Journal of Infectious Diseases v.10 n.5 2006
|
| Direitos: |
info:eu-repo/semantics/openAccess
|
|
